PMID- 6087518
OWN - NLM
STAT- MEDLINE
DCOM- 19840904
LR  - 20190727
IS  - 0041-1132 (Print)
IS  - 0041-1132 (Linking)
VI  - 24
IP  - 4
DP  - 1984 Jul-Aug
TI  - Effect of perfluorochemical blood substitutes on human neutrophil function.
PG  - 343-7
AB  - This investigation was undertaken to determine the influence of perfluorochemical 
      blood substitutes (PFCs) on human neutrophil function. Neutrophils isolated from 
      blood of healthy donors were incubated at 37 degrees C for 1 hour with 25 percent 
      Oxypherol (perfluorotributylamine) or Fluosol-DA (perfluorodecalin and 
      perfluorotripropylamine) in the presence of fresh autologous serum. In comparison 
      to cells incubated with Hank's balanced salt solution (buffer), neutrophils 
      exposed to PFCs were markedly inhibited in their chemotactic and phagocytic 
      responses. With 25 percent PFCs, chemotaxis to zymosan-activated serum was 
      inhibited to approximately 25 percent of control by Fluosol-DA and 11 percent by 
      Oxypherol. Phagocytosis of polystyrene beads in the presence of fresh serum was 
      decreased to 52 and 50 percent of control by both Oxypherol and Fluosol-DA, 
      respectively. Neutrophils exposed to PFCs aggregated slower and with an extended 
      activation time upon addition of phorbol myristate acetate (PMA). When activated 
      with n-formyl-methionyl-leucyl-phenylalanine (FMLP), neutrophils exposed to PFCs 
      aggregated at a faster rate but with a longer lag phase in comparison to control 
      cells. Neutrophil superoxide (O-2) release stimulated by PMA also was depressed 
      by prior exposure of cells to Oxypherol (6 nmoles O-2/1.5 X 10(6) neutrophils) 
      compared to buffer (32 nmoles O-2/1.5 X 10(6) neutrophils). PMA-stimulated 
      neutrophil adherence was depressed significantly by prior exposure to Fluosol-DA 
      compared to control. In contrast, Oxypherol had insignificant influence on 
      stimulated adherence. Since PFCs have a profound influence on several important 
      neutrophil functions, patients receiving PFC should be monitored closely for 
      possible infectious complications.
FAU - Virmani, R
AU  - Virmani R
FAU - Fink, L M
AU  - Fink LM
FAU - Gunter, K
AU  - Gunter K
FAU - English, D
AU  - English D
LA  - eng
GR  - AI-17950/AI/NIAID NIH HHS/United States
GR  - AI-21168/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Transfusion
JT  - Transfusion
JID - 0417360
RN  - 0 (Blood Substitutes)
RN  - 0 (Drug Combinations)
RN  - 0 (Fluorocarbons)
RN  - 0 (Hydroxyethyl Starch Derivatives)
RN  - 11062-77-4 (Superoxides)
RN  - 3702Y1HQ6O (perfluorotributylamine)
RN  - 75216-20-5 (glucose, glycerol, hydroxyethyl starch, perfluorodecalin, 
      perfluorotripropylamine, pluronic F-68, salts, yolk phospholipids drug 
      combination)
SB  - IM
MH  - Blood Substitutes/*pharmacology
MH  - Cell Adhesion/drug effects
MH  - Cell Aggregation/drug effects
MH  - Cell Survival/drug effects
MH  - Chemotaxis, Leukocyte/drug effects
MH  - Drug Combinations/pharmacology
MH  - Fluorocarbons/*pharmacology
MH  - Humans
MH  - Hydroxyethyl Starch Derivatives
MH  - Neutrophils/*drug effects
MH  - Phagocytosis/drug effects
MH  - Superoxides/metabolism
EDAT- 1984/07/01 00:00
MHDA- 1984/07/01 00:01
CRDT- 1984/07/01 00:00
PHST- 1984/07/01 00:00 [pubmed]
PHST- 1984/07/01 00:01 [medline]
PHST- 1984/07/01 00:00 [entrez]
AID - 10.1046/j.1537-2995.1984.24484275579.x [doi]
PST - ppublish
SO  - Transfusion. 1984 Jul-Aug;24(4):343-7. doi: 
      10.1046/j.1537-2995.1984.24484275579.x.